The Wall Street Journal
: Drug Makers Recall Omontys Anemia Medication
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline. The move affects thousands of kidney-disease patients who have been receiving the drug, promoted as a cheaper and more convenient alternative to Amgen Inc.'s blockbuster Epogen, which holds a near-monopoly in treating anemia in that market (Walker, 2/24).
This is part of Kaiser Health News' Daily Report - a summary of health policy coverage from major news organizations. The full summary of the day's news can be found here and you can sign up for e-mail subscriptions to the Daily Report here. In addition, our staff of reporters and correspondents file original stories each day, which you can find on our home page.